Skip to content

Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients

The Impact of Different Preload Strategies on Hemodynamics During Anesthesia Induction in TAVR Patients

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07329660
Acronym
CHAIN-T
Enrollment
116
Registered
2026-01-09
Start date
2026-02-16
Completion date
2026-12-31
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia Induction, Hemodynamic Stability, Transcatheter Aortic Valve Replacement

Brief summary

The purpose of this study is to evaluate whether the administration of 5 ml/kg of colloid solution prior to anesthesia induction, compared with 5 ml/kg of lactated Ringer's solution, can reduce hemodynamic fluctuations during the induction period (defined as the first 15 minutes after induction) in patients undergoing Transcatheter Aortic Valve Replacement (TAVR).

Interventions

5 ml/kg of hydroxyethyl starch 130/0.4 electrolyte injection is administered by infusion pump over 15 minutes before anesthesia induction.

DRUGLactate Ringer's Solution

5 ml/kg of sodium lactate Ringer's solution is administered before anesthesia induction.

Sponsors

Air Force Military Medical University, China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years; * Patients scheduled to undergo elective TAVR under general anesthesia;

Exclusion criteria

* Allergy to hydroxyethyl starch, its components, and/or sodium lactate Ringer's solution, or a history of colloidal allergy; * Severe cardiac dysfunction (ejection fraction\[EF\] \< 35%); * Severe renal dysfunction (creatinine \> 132 μg/L and/or requiring renal replacement therapy); * Morbid obesity (body mass index\[BMI\] \> 37.5 kg/m² or \> 32.5 kg/m² with metabolic diseases); * Severe hepatic dysfunction ; * Severe electrolyte disturbances ; * Patients with preoperative intracranial hypertension requiring dehydration therapy; * Expected postoperative hospital stay \< 24 hours; * Patients scheduled for multiple surgeries during this hospitalization.

Design outcomes

Primary

MeasureTime frameDescription
The area under curve (AUC) of the change in mean arterial pressure from baseline during the induction period.induction period, at an average of 15 minutesThe AUC below baseline MAP is calculated as: ∑ (((Si - Sbaseline)+(Si-1 - Sbaseline))/2 × ΔX) where Sbaseline is the baseline MAP, Si is the MAP at minute i (i = 0.5, 1, 1.5…15), and ΔX is the time interval between measurements.

Secondary

MeasureTime frameDescription
Incidence of post-induction hemodynamic instability, defined as arterial pressure (MAP)< 65 mmHg or a decrease of more than 20% from baseline within 15 minutes after induction.15 minutes after induction
Intraoperative use of vasoactive drugs.Intraoperative period, at an average of 2 hours
Sequential Organ Failure Assessment(SOFA )score on the first postoperative dayThe first postoperative day, at 24 hours after surgerySOFA score grades organ dysfunction from 0 (normal) to 4 (most abnormal) for six organ systems . The total score is the sum of all six sub-scores, ranging from 0 to 24 . The higher score means the worse organ function.
Length of hospital stay.The duration of the patient's hospitalization after the initial surgery, at an average of 5 days.
Proportion of patients admitted to the intensive care unit (ICU) after surgeryDuring the postoperative period prior to discharge (at an average of 5 days)
In-hospital all-cause mortalityDuring the postoperative period prior to discharge (at an average of 5 days)
All-cause mortality within 30 days postoperatively30 days after surgery
Proportion of patients receiving renal replacement therapy during the 30-day postoperative observation period30 days after surgery

Contacts

CONTACTZhihong Lu
deerlu23@163.com86-13891975018
STUDY_CHAIRHailong Dong

Air Force Medical University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 26, 2026